News Column

GrowBLOX Sciences, Inc. Names Chief Science Officer and Member of the Board of Directors

June 30, 2014

By a News Reporter-Staff News Editor at Clinical Trials Week -- GrowBLOX Sciences, Inc. (OTCQB: GBLX) a biotechnology and research company, announced that The Company has named its Chief Science Officer and Member of the Board of Directors, Dr. Andrea Small-Howard, PhD, MBA. Dr. Small-Howard comes to GrowBLOX Sciences with an extensive background in Biotechnology and Biopharmaceutical products (see also GrowBLOX Sciences, Inc.).

Dr. Andrea Small-Howard leverages broad industry knowledge with a focus on managing new product development that can be commercialized in the U.S. and selected international markets. She employs an integrated approach to product commercialization, as her core product development perspective is augmented with manufacturing, regulatory, supply chain and corporate alliance experience. Dr. Small-Howard received her AB from Occidental College, in addition to receiving both an MBA and a PhD in Biological Sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, she lead a project group dedicated to the study of cannabinoids in the immune system and published two peer-reviewed papers on the subject. She also screened synthetic cannabinoids at the in vitro and preclinical levels. Dr. Small-Howard has previously screened licensing candidates in other biotech disciplines and developed biopharma products that are currently on the market. She has also written and filed patents and global regulatory approvals.

GrowBLOX Sciences, CEO, Craig Ellins said, "I couldn't be happier to have Andrea on board. We have been building a business model based on our proprietary technology and with someone as talented and skilled in biotechnology as Andrea, we have the research and resources to help her build on the momentum of our product pipeline. Now that the FDA has fast tracked clinical trials for certain cannabinoid medicines, Andrea's experience in FDA product trials will position our team of scientists to a nutraceutical and pharmaceutical approved market."

Keywords for this news article include: Biotechnology, Legal Issues, GrowBLOX Sciences Inc..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Clinical Trials Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters